Schwach Verena, Cofiño-Fabres Carla, Ten Den Simone A, Passier Robert
Department of Applied Stem Cell Technologies, TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands.
Department of Anatomy and Embryology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
J Pers Med. 2022 Apr 13;12(4):628. doi: 10.3390/jpm12040628.
Human pluripotent stem cell (hPSC)-derived cardiomyocytes have proven valuable for modeling disease and as a drug screening platform. Here, we depict an optimized protocol for the directed differentiation of hPSCs toward cardiomyocytes with an atrial identity by modulating the retinoic acid signaling cascade in spin embryoid bodies. The crucial steps of the protocol, including hPSC maintenance, embryoid body (EB) differentiation, the induction of cardiac mesoderm, direction toward the atrial phenotype, as well as molecular and functional characterization of the cardiomyocytes, are described. Atrial cardiomyocytes (AMs) can be generated within 14 days. Most importantly, we show that induction of the specific retinoic acid receptor alpha (RARα) increased the efficiency of atrial differentiation to 72% compared with 45% after modulating the retinoic acid (RA) pathway with all-trans RA (atRA). In contrast, the induction of RARβ signaling only had a minor impact on the efficiency of atrial differentiation (from about 45% to 50%). Similarly, the total yield of AM per EB of 5000 hPSCs was increased from 10,350 (2.07 per hPSC) to 16,120 (3.22 per hPSC) while selectively modulating RARα signaling. For further purification of the AMs, we describe a metabolic selection procedure that enhanced the AM percentage to more than 90% without compromising the AM yield (15,542 per EB, equal to 3.11 per hPSC) or functionality of the AMs as evaluated by RNAseq, immunostaining, and optical action potential measurement. Cardiomyocytes with distinct atrial and ventricular properties can be applied for selective pharmacology, such as the development of novel atrial-specific anti-arrhythmic agents, and disease modeling, including atrial fibrillation, which is the most common heart rhythm disorder. Moreover, fully characterized and defined cardiac subtype populations are of the utmost importance for potential cell-based therapeutic approaches.
人类多能干细胞(hPSC)衍生的心肌细胞已被证明在疾病建模和作为药物筛选平台方面具有重要价值。在此,我们描述了一种优化方案,通过调节旋转胚状体中的视黄酸信号级联反应,将hPSC定向分化为具有心房特征的心肌细胞。该方案的关键步骤包括hPSC的维持、胚状体(EB)分化、心脏中胚层的诱导、向心房表型的定向以及心肌细胞的分子和功能表征。心房心肌细胞(AM)可在14天内生成。最重要的是,我们表明,与用全反式视黄酸(atRA)调节视黄酸(RA)途径后45%的心房分化效率相比,诱导特异性视黄酸受体α(RARα)可将心房分化效率提高到72%。相比之下,诱导RARβ信号传导对心房分化效率的影响较小(从约45%提高到50%)。同样,在选择性调节RARα信号传导时,每个含有5000个hPSC的EB的AM总产量从10350个(每个hPSC 2.07个)增加到16120个(每个hPSC 3.22个)。为了进一步纯化AM,我们描述了一种代谢筛选程序,该程序可将AM百分比提高到90%以上,同时不影响AM产量(每个EB 15542个,相当于每个hPSC 3.11个)或通过RNA测序、免疫染色和光学动作电位测量评估的AM功能。具有不同心房和心室特性的心肌细胞可用于选择性药理学,如新型心房特异性抗心律失常药物的开发,以及疾病建模,包括心房颤动,这是最常见的心律失常。此外,充分表征和定义的心脏亚型群体对于潜在的基于细胞的治疗方法至关重要。